Phillips Wealth Planners LLC Grows Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Phillips Wealth Planners LLC increased its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 47.0% during the first quarter, HoldingsChannel.com reports. The institutional investor owned 4,042 shares of the company’s stock after acquiring an additional 1,292 shares during the period. Phillips Wealth Planners LLC’s holdings in Novo Nordisk A/S were worth $262,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in NVO. Revolve Wealth Partners LLC grew its holdings in shares of Novo Nordisk A/S by 8.7% during the fourth quarter. Revolve Wealth Partners LLC now owns 2,490 shares of the company’s stock worth $214,000 after buying an additional 200 shares during the last quarter. MONECO Advisors LLC grew its holdings in shares of Novo Nordisk A/S by 19.5% during the fourth quarter. MONECO Advisors LLC now owns 2,359 shares of the company’s stock worth $203,000 after buying an additional 385 shares during the last quarter. IFP Advisors Inc grew its holdings in shares of Novo Nordisk A/S by 5.4% during the fourth quarter. IFP Advisors Inc now owns 11,558 shares of the company’s stock worth $994,000 after buying an additional 594 shares during the last quarter. Cavalier Investments LLC grew its holdings in shares of Novo Nordisk A/S by 4.3% during the fourth quarter. Cavalier Investments LLC now owns 23,429 shares of the company’s stock worth $2,015,000 after buying an additional 960 shares during the last quarter. Finally, Lake Street Advisors Group LLC grew its holdings in shares of Novo Nordisk A/S by 5.5% during the fourth quarter. Lake Street Advisors Group LLC now owns 15,470 shares of the company’s stock worth $1,331,000 after buying an additional 811 shares during the last quarter. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

NVO stock opened at $67.37 on Thursday. The firm has a 50 day moving average of $68.70 and a 200-day moving average of $77.86. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $145.99. The company has a current ratio of 0.74, a quick ratio of 0.56 and a debt-to-equity ratio of 0.70. The company has a market cap of $300.81 billion, a price-to-earnings ratio of 19.93, a PEG ratio of 1.26 and a beta of 0.66.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Wednesday, May 7th. The company reported $0.92 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $0.92. Novo Nordisk A/S had a net margin of 34.52% and a return on equity of 80.94%. The company had revenue of $11.87 billion during the quarter. As a group, equities analysts expect that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently issued reports on the company. BMO Capital Markets reissued a “market perform” rating and set a $64.00 price target (down previously from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Wall Street Zen raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Saturday, June 14th. BNP Paribas began coverage on Novo Nordisk A/S in a report on Tuesday, April 15th. They issued an “underperform” rating on the stock. Stifel Nicolaus lowered Novo Nordisk A/S from a “buy” rating to a “hold” rating in a report on Monday, March 3rd. Finally, Kepler Capital Markets raised Novo Nordisk A/S from a “hold” rating to a “buy” rating in a report on Thursday, March 13th. Two research analysts have rated the stock with a sell rating, five have given a hold rating, four have given a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $112.00.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.